Urocortin (UCN) refers to a family of three peptides — Urocortin 1 (Ucn1), Urocortin 2 (Ucn2, also called stresscopin-related peptide), and Urocortin 3 (Ucn3, also called stresscopin) — that belong to the corticotropin-releasing factor (CRF) superfamily. While CRF is primarily known for its role in the hypothalamic-pituitary-adrenal (HPA) axis and stress response, the urocortins have emerged as important cardiovascular peptides with distinct receptor selectivity and therapeutic potential.

Overview

The CRF peptide superfamily consists of four mammalian members: CRF, Urocortin 1, Urocortin 2, and Urocortin 3. These peptides act through two G protein-coupled receptors — CRF type 1 receptor (CRF1R) and CRF type 2 receptor (CRF2R) — with distinct selectivity profiles. CRF preferentially binds CRF1R and mediates the classical HPA stress response. Urocortin 1 binds both CRF1R and CRF2R with high affinity. Urocortin 2 and Urocortin 3 are selective CRF2R agonists, which is therapeutically significant because CRF2R mediates the cardioprotective and cardiovascular effects while CRF1R mediates anxiety-like and stress-related effects.

Urocortin 1 (40 amino acids) was discovered in 1995 by Vaughan et al. from rat brain tissue. Urocortin 2 (38 amino acids) and Urocortin 3 (38 amino acids) were identified subsequently. All three urocortins are expressed in the heart, with CRF2R being the predominant CRF receptor subtype on cardiomyocytes. The cardiovascular effects of CRF2R activation include positive inotropy, vasodilation, coronary vasodilation, and protection against ischemia-reperfusion injury — a combination that makes Ucn2 particularly attractive for heart failure treatment.

CRF2R exists in three splice variants: CRF2R-alpha (primarily CNS), CRF2R-beta (primarily peripheral tissues including heart), and CRF2R-gamma. The cardiovascular effects of urocortins are primarily mediated through CRF2R-beta on cardiomyocytes, vascular smooth muscle cells, and endothelial cells.

Mechanism of Action

Urocortins, particularly Ucn2, activate CRF2R to produce cardiovascular and metabolic effects through multiple signaling pathways:

CRF2R/Gs/cAMP/PKA Pathway (Positive Inotropy): CRF2R is a Gs-coupled GPCR. Ucn2 binding activates adenylyl cyclase, increasing intracellular cAMP and activating protein kinase A (PKA). In cardiomyocytes, PKA phosphorylates L-type calcium channels (increasing calcium influx), ryanodine receptors (increasing sarcoplasmic reticulum calcium release), phospholamban (increasing SERCA2a activity and calcium reuptake), and troponin I (enhancing relaxation). This mechanism produces both positive inotropy (increased contractile force) and positive lusitropy (faster relaxation), improving both systolic and diastolic function.

Vasodilation via cAMP/PKA and NO: In vascular smooth muscle, CRF2R activation increases cAMP, which activates PKA and produces vasodilation through reduction of intracellular calcium. Ucn2 also stimulates NO release from endothelial cells, producing endothelium-dependent vasodilation. The combined inotropic and vasodilatory effects produce a favorable hemodynamic profile — increased cardiac output with decreased afterload.

PI3K/Akt Cardioprotection: Ucn2 activates the PI3K/Akt survival pathway, which phosphorylates and inhibits pro-apoptotic proteins (Bad, caspase-9), activates anti-apoptotic proteins (Bcl-2), and opens mitochondrial KATP channels. This reperfusion injury salvage kinase (RISK) pathway is central to Ucn2's cardioprotective effects against ischemia-reperfusion injury and reduces infarct size when administered before or at the time of reperfusion.

ERK1/2 and p38 MAPK Signaling: Ucn2 activates ERK1/2, which promotes cell survival, and p38 MAPK, which can modulate both protective and stress responses depending on the duration and context of activation. In the heart, Ucn2-mediated ERK1/2 activation contributes to cardioprotection and anti-hypertrophic effects.

Neurohormonal Suppression: Ucn2 suppresses the sympathetic nervous system and reduces circulating levels of catecholamines, endothelin-1, and vasopressin. This neurohormonal modulation is particularly beneficial in heart failure, where neurohormonal overactivation drives disease progression.

Anti-inflammatory Effects: Ucn2/CRF2R signaling reduces NF-kappaB activation, decreases pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6), and promotes anti-inflammatory cytokine release (IL-10). These effects may contribute to cardiac protection in inflammatory cardiomyopathies and ischemia-reperfusion injury.

Metabolic Effects: Ucn2 increases insulin sensitivity, glucose uptake in skeletal muscle (via AMPK activation and GLUT4 translocation), and suppresses appetite through central CRF2R activation. These metabolic properties have prompted investigation of urocortins for obesity and type 2 diabetes.

Research

Safety Profile

Urocortin peptides have been administered intravenously to healthy volunteers and heart failure patients in Phase 1/2 clinical studies with generally favorable safety profiles. The primary hemodynamic effects — decreased blood pressure and increased heart rate — are pharmacologically predictable and dose-dependent. In the Davis et al. (2007) heart failure trial, Ucn2 infusion at 100 mcg/kg/h was well tolerated with no serious adverse events. Blood pressure decreased modestly (5-10 mmHg systolic), and a small compensatory increase in heart rate was observed. No arrhythmias, chest pain, or ischemic symptoms were reported. Stirrat et al. confirmed the safety of Ucn2 at doses up to 240 mcg/kg/h in heart failure patients, with hypotension being the dose-limiting adverse effect.

Theoretical concerns include HPA axis activation (via CRF receptor cross-reactivity) and cortisol elevation. However, Ucn2's selectivity for CRF2R over CRF1R minimizes this risk, and clinical studies have shown that Ucn2 actually suppresses ACTH levels rather than stimulating them. Ucn1, which binds both CRF1R and CRF2R, has greater potential for HPA axis stimulation and anxiety-like effects at high doses. Mild nausea and flushing have been reported during Ucn infusion studies. No hepatotoxicity, nephrotoxicity, or immunogenicity has been observed. Long-term safety data are limited, as clinical studies have been short-term infusion protocols.

Clinical Research Protocols

• Ucn2 infusion (HF — Davis et al.): 100 mcg/kg/h IV infusion for 1 hour in stable chronic heart failure (NYHA II-III). Hemodynamic monitoring with right heart catheterization. The study demonstrated increased cardiac output (+27%), decreased SVR (-25%), and neurohormonal suppression.
• Ucn2 dose-ranging (Rademaker et al.): Incremental doses of 25, 50, and 100 mcg/kg/h IV in heart failure patients, each for 1 hour, to characterize dose-response relationships.
• Ucn2/Ucn3 comparative study (Stirrat et al.): Ucn2 (20-240 mcg/kg/h) and Ucn3 (100-4800 mcg/kg/h) IV infusion in heart failure patients, demonstrating dose-dependent hemodynamic effects with Ucn2 being more potent.
• Monitoring: Invasive hemodynamic monitoring (right heart catheterization), continuous ECG, blood pressure every 5 minutes, serial blood sampling for neurohormones (BNP, catecholamines, endothelin-1, ACTH, cortisol).
• Key trials: Davis et al. 2007 JACC/Eur Heart J (Ucn2 in HF), Rademaker et al. 2011 (dose-ranging), Stirrat et al. 2016 (Ucn2 vs Ucn3 in HF).

Subpopulation Research

• Chronic heart failure (HFrEF): The primary therapeutic target. Ucn2 improves hemodynamics, suppresses neurohormones, and may favorably remodel the failing heart (PMID: 17239718). Benefits demonstrated in NYHA class II-III with LVEF <40%.
• Ischemic heart disease: Ucn1 and Ucn2 reduce infarct size in animal models when administered at reperfusion. Translation to clinical cardioprotection during primary PCI or cardiac surgery is a key research direction.
• Pulmonary hypertension: CRF2R activation by urocortins produces pulmonary vasodilation. Preclinical studies show Ucn2 reduces pulmonary artery pressure in PAH models, though clinical data are lacking.
• Septic cardiomyopathy: Preclinical evidence of Ucn1/Ucn2 protection against sepsis-induced myocardial depression through anti-inflammatory and anti-apoptotic mechanisms (PMID: 17148668).
• Type 2 diabetes/metabolic syndrome: Ucn2 improves insulin sensitivity and glucose uptake through AMPK activation. Heart failure patients with comorbid diabetes may derive dual cardiovascular and metabolic benefit (PMID: 16373423).
• Post-cardiac surgery: Urocortins may protect against cardioplegic arrest and cardiopulmonary bypass-induced myocardial injury. Preclinical studies show benefit when added to cardioplegia solutions.
• Stress-related disorders: Central CRF2R activation by Ucn2/Ucn3 produces anxiolytic and stress-recovery effects, with potential applications in anxiety disorders and PTSD.

Pharmacokinetic Profile

Ongoing & Future Research

• Long-acting urocortin formulations: Development of sustained-release urocortin formulations (PEGylation, depot injections, gene therapy) to overcome the limitation of short plasma half-lives and enable chronic treatment of heart failure.
• Selective CRF2R agonists: Small molecule CRF2R agonists with oral bioavailability and improved pharmacokinetics are in preclinical development, which would enable chronic dosing for heart failure and metabolic disease.
• Urocortin gene therapy: AAV-mediated Ucn2 gene delivery has shown remarkable results in preclinical heart failure models, producing sustained cardiac improvement for weeks to months after a single injection. Gao et al. demonstrated that IV AAV8-Ucn2 in mice with heart failure improved LV function, reduced fibrosis, and enhanced survival. Gao et al. (2013) — JACC Heart Fail.
• Cardioprotection in clinical practice: Translation of preclinical ischemia-reperfusion protection to human settings — potential use during primary PCI for STEMI, cardiac surgery with cardiopulmonary bypass, and organ transplantation.
• Dual cardiovascular-metabolic therapy: Urocortins' combined inotropic, vasodilatory, anti-fibrotic, and insulin-sensitizing properties make them candidates for treating heart failure with comorbid metabolic syndrome — a common and challenging clinical phenotype.
• Biomarker applications: Circulating urocortin levels as prognostic biomarkers in heart failure and acute coronary syndromes, potentially identifying patients who would benefit most from CRF2R agonist therapy.